Company environment · Targeted small molecules · clinical operations
Academic oncology center clinical trial site operations
Pivotal Phase 3 trial; site activation and protocol-amendment governance.
1What does this company do?
Academic oncology investigator site conducting industry-sponsored clinical trials under GCP.
2Where is the product on its way to patients?
Oral targeted oncology therapy in a pivotal Phase 3 advanced breast cancer trial.
- 1Discovery & Lead Selection
- 2IND-Enabling Nonclinical
- 3Clinical Development (IND / CTA)
- The product is here
- 4Registration & Dossier Review
- 5Approval & Launch Readiness
- 6Commercial Lifecycle & GMP
3What is happening right now?
Central-IRB submission, sponsor Site Initiation Visit (SIV) readiness, and protocol-amendment re-consent gates are under review.
4Tasks
11 tasks in the 81-task Biopharma Bench V0.2 suite, graded against expert rubric criteria.
Sealed partner records & open showcases
This environment is reconstructed from a confidential drug or device program, so its records, tasks, and rubrics remain sealed.
To inspect complete workspaces, candidate deliverables, trajectories, and rubric criteria end to end, open the two public companion showcases:
Havenor Therapeutics (synthetic sterile-injectables CMC/MSAT) →
Broad Institute (public FDA CDER IND 167326 record) →